Analyst Ratings for Genmab (GMXAY)
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/1/2018 | H.C. Wainwright | Raghuram Selvaraju | New Coverage | Buy (N/A) |
N/A (N/A) |
16.04 (18.35) |
14.4% | Details |
| 9/10/2018 | BofA Securities | Graham Perry | Downgrade | Underperform (Buy) |
N/A (N/A) |
16.49 (18.35) |
11.28% | Details |
